Literature DB >> 26273253

Hypocholesterolemic effects of Kluyveromyces marxianus M3 isolated from Tibetan mushrooms on diet-induced hypercholesterolemia in rat.

Yuanhong Xie1, Hongxing Zhang1, Hui Liu1, Lixia Xiong1, Xiuzhi Gao1, Hui Jia1, Zhengxing Lian2, Nengsheng Tong3, Tao Han1.   

Abstract

To investigate the effects of Kluyveromyces marxianus M3 isolated from Tibetan mushrooms on diet-induced hypercholesterolemia in rats, female Wistar rats were fed a high-cholesterol diet (HCD) for 28 d to generate hyperlipidemic models. Hyperlipidemic rats were assigned to four groups, which were individually treated with three different dosages of K. marxianus M3+HCD or physiological saline+HCD via oral gavage for 28 d. The total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels in the serum and liver of the rats were measured using commercially available enzyme kits. In addition, the liver morphology was also examined using hematoxylin and eosin staining and optical microscopy. According to our results, the serum and liver TC, TG, LDL-C levels and atherogenic index (AI) were significantly decreased in rats orally administered K. marxianus M3 (p <0.01), and the HDL-C levels and anti atherogenic index (AAI) were significantly increased (p <0.01) compared to the control group. Moreover, K. marxianus M3 treatment also reduced the build-up of lipid droplets in the liver and exhibited normal hepatocytes, suggesting a protective effect of K. marxianus M3 in hyperlipidemic rats.

Entities:  

Keywords:  Kluyveromyces marxianus; high-cholesterol diet; hypercholesterolemia

Mesh:

Substances:

Year:  2015        PMID: 26273253      PMCID: PMC4507530          DOI: 10.1590/S1517-838246220131278

Source DB:  PubMed          Journal:  Braz J Microbiol        ISSN: 1517-8382            Impact factor:   2.476


Introduction

Hypercholesterolemia is considered to be a risk factor of cardiovascular disease and is the leading cause of morbidity and mortality in many countries (Law ). Elevated serum cholesterol levels are widely recognized as a contributing risk factor for the development of cardiovascular diseases, such as atherosclerosis, coronary heart disease and stroke. It has been reported that a 1% reduction in serum cholesterol could reduce the risk of coronary heart disease by 2 to 3% (Manson ). The decrease in cholesterol levels could be achieved by appropriate food intake, such as low-cholesterol, low-fat diets (Lora ), dietary fiber (Jiménez ; Theuwissen ), and yogurts containing specific probiotics (Akalin ; Danielson ). Recently, some studies have demonstrated that the hypocholesterolemic effects of probiotics have resulted in an increased interest in this treatment modality, which is less expensive and may be considered a "natural health remedy." Several studies evaluating this effect have found that some lactobacilli or bifidobacteria can exhibit hypocholesterolemic properties in animal models (Fukushima and Nakano 1996; Gilliland et al., 1989; Nguyen ; Kumar ) and humans (Agerbaek ; Anderson and Gilliland 1999; Xiao ). However, the hypocholesterolemic mechanism of lactic acid bacteria is still no clearly understood, although the bacteria appear to contribute to increased fecal excretion of bile acids and thereby improved overall hepatic cholesterol homeostasis (Jeun ). Moreover, some reports have failed to show hypocholesterolemic effects of probiotics (Hatakka ; Simons ). Thus, additional studies are required to strengthen the proposed hypotheses and to improve our understanding of how bacteria affect cholesterol metabolism, which might result in the more appropriate use of probiotics. Kefir has been widely recommended in western countries for consumption by healthy people to lower the risk of chronic diseases and has also been provided to some patients for the clinical treatment of a number of gastrointestinal and metabolic diseases, hypertension, and allergy (St-Onge ). Yogurt prepared from Tibetan mushrooms and milk has an extraordinary taste and provides excellent nutrition. Tibetan kefir has a granular structure due to the presence of symbiotic microorganisms, such as Lactobacillus and yeast (Simova ). In addition, kefir culture was reported to exhibit the ability to assimilate cholesterol in milk (Vujicic ). Furthermore, Liu demonstrated the hypocholesterolemic effect of kefir milk in male hamsters fed with a cholesterol-enriched diet. However, St-Onge obtained a conflicting result and reported that kefir consumption did not result in the lowering of plasma lipid concentrations, although kefir resulted in increasing fecal isobutyric, isovaleric, and propionic acids as well as the total amount of fecal short chain fatty acids. Moreover, some researchers have found that kefir-fermented milk can decrease plasma cholesterol levels and can promote cancer resistance. Furthermore, it has antioxidant properties, including a role in immune regulation, and can help to protect against pathogenic bacteria and spoilage organisms, as well as assist in the conservation of predominant gastrointestinal probiotic flora (Abd El-Gawad ; Mathara ; Nguyen ; Akalin ). The objective of this study was to evaluate the effects of Kluyveromyces marxianus M3 yeast isolated from Tibetan mushrooms on lowering cholesterol in rats.

Materials and Methods

Microbial cultures

K. marxianus M3 was isolated from Tibetan mushrooms and was cultured by a resident of Baicheng, Jilin province, China (Liu ). M3 strains (1–2%) were inoculated into 10 mL potato lactose liquid medium and grown at 28 °C for 24. The culture was centrifuged and diluted with 0.9% saline water to obtain a preparation of 2.0 × 107 cfu/mL.

Animals, diets and experimental design

Forty female Wistar rats (aged 3 weeks) with a weight of 140 ± 10 g were obtained from the Academy of Military Medical Sciences (Beijing, China). All rats were individually housed at a constant temperature and humidity (18–24 °C, 60%) with a 12 h light/dark cycle. After 1 week of acclimatization, all of the rats were fed a high-cholesterol diet (78.8% basic diet, 1% cholesterol, 10% egg yolk, 10% lard, 0.2% cholate, w/w) for 28 d. In addition, the rats were randomly assigned to four groups (n = 10), respectively. Group (NM): normal rats fed a standard high-cholesterol diet and physiological saline (5 mL/kg); Group α (LD): normal rats fed a standard high-cholesterol diet and K. marxianus M3 (5 mL/kg); Group β (MD): normal rats fed a standard high-cholesterol diet and K. marxianus M3 (10 mL/kg); Group IV (HD): normal rats fed a standard high-cholesterol diet and K. marxianus M3 (20 mL/kg). The rats were intragastrically administered for 28 d, and food and water consumption and body weight were recorded daily. At the end of the feeding period, all rats were anesthetized by isoflurane and sacrificed by cervical dislocation. The kidney, heart and liver were immediately excised, and the serum was separated from the blood. The liver, heart and kidney were excised, rinsed in ice-cold physiological saline, weighed, and then stored at −20 °C.

Serum lipid analysis

The samples were allowed to stand for 10 min and then centrifuged at 3500 r/min for 15 min, where the sediment was subsequently discarded. The TC (total cholesterol), TG (triglyceride), HDL-C (high density lipoprotein-cholesterol), and LDL-C (low density lipoprotein-cholesterol) levels were analyzed using kits (Bio-technology and Science Incorporation) and a fully automatic biochemical analyzer (Hitachi, Japan). The atherosclerosis index (AI) was calculated as follows: AI = (total cholesterol - HDL cholesterol)/HDL cholesterol.

Liver lipid analysis

Isolated livers were weighed after rinsing with phosphate-buffered saline and blotted dry with filter paper. Each liver was homogenized in 20 volumes of extraction solution (chloroform: methanol = 2:1; v/v) and agitated for 60 min at room temperature (Zhao ). Liver cholesterol and triacylglycerols were measured using the kits previously described.

Morphology of liver

Fresh livers of rats were fixed with 4% paraformaldehyde for 24 h, gradually dehydrated in a graded series of ethanol, clarified in xylene, and embedded in paraffin wax. The hematoxylin and eosin stained livers were observed using an optical microscope (Wang ).

Statistical analysis

All data were expressed as the mean ± SD. Statistical analysis was performed using SPSS 13.0 software. Differences between the groups were analyzed by One-Way ANOVA followed by Duncan's multiple range tests. Statistical significance was considered at p <0.01.

Results

Effect on plasma lipid profiles

The effects of K. marxianus M3 live yeast supplementation on the serum lipid levels of rats are presented in Table 1. The rats subjected to a high cholesterol diet or high cholesterol diet with K. marxianus M3 had no obvious difference in body weight (BW) during the entire 7 weeks of experiments. And high cholesterol diet dramatically increased the serum TC, TG and LDL-C levels of rats in NM group, which demonstrated the hyperlipidemic model was set up successfully. In addition, oral administration of K. marxianus M3 for 7 weeks significantly decreased (p <0.01) the serum TC, TG and LDL-C levels of rats compared with the NM groups. In contrast, the serum HDL-C levels in the K. marxianus M3 supplemented rats significantly increased (p <0.01, p <0.05) compared to that in NM group after 7 weeks of administration.
Table 1

Effect of Kluyveromyces marxianus M3 from Tibetan Kefir on plasma lipid profiles of rats ( ± s, n = 6).

NMLDMDHD




1 week3 week5 week7 week1 week3 week5 week7 week1 week3 week5 week7 week1 week3 week5 week7 week
BW (g)155.1 ± 5.1204.9 ± 9.9251.9 ± 16.9273.2 ± 20.8154.3 ± 7.3204.4 ± 11.6246.4 ± 14.6268.1 ± 20.9156.2 ± 6.8206.5 ± 10.5244.1 ± 15.9268.3 ± 21.3155.4 ± 8.6205.5 ± 12.5247.3 ± 17.3272.2 ± 21.2
TC (mmol/L)2.86 ± 0.963.18 ± 1.064.76 ± 1.504.94 ± 1.902.84 ± 0.753.07 ± 0.953.36 ± 1.26** 2.75 ± 0.76** 2.72 ± 0.703.34 ± 1.353.39 ± 1.41** 2.42 ± 0.62** 2.58 ± 0.603.81 ± 1.434.10 ± 1.823.17 ± 1.09**
TG (mmol/L)0.39 ± 0.230.24 ± 0.200.37 ± 0.120.51 ± 0.230.30 ± 0.150.25 ± 0.180.33 ± 0.090.31 ± 0.07** 0.37 ± 0.210.41 ± 0.280.37 ± 0.110.36 ± 0.12** 0.33 ± 0.120.19 ± 0.130.34 ± 0.120.33 ± 0.12**
HDL-C (mmol/L)0.70 ± 0.160.48 ± 0.060.45 ± 0.080.43 ± 0.140.70 ± 0.150.60 ± 0.200.52 ± 0.100.62 ± 0.18** 0.64 ± 0.140.51 ± 0.170.46 ± 0.100.50 ± 0.17DD 0.58 ± 0.140.52 ± 0.170.40 ± 0.100.45 ± 0.10DD
LDL-C (mmol/L)0.64 ± 0.201.04 ± 0.371.57 ± 0.511.58 ± 0.610.65 ± 0.200.82 ± 0.250.69 ± 0.34** 0.63 ± 0.33** 0.56 ± 0.161.04 ± 0.430.74 ± 0.47** 0.88 ± 0.41** 0.64 ± 0.170.94 ± 0.540.95 ± 0.58** 1.08 ± 0.41**
AI2.85 ± 0.355.67 ± 0.5310.11 ± 0.9610.11 ± 0.913.01 ± 0.244.01 ± 0.345.67 ± 0.52** 3.35 ± 0.25** 3.17 ± 0.265.67 ± 0.516.14 ± 0.46** 4.00 ± 0.25** 3.55 ± 0.216.14 ± 0.4610.00 ± 0.906.14 ± 0.74**
AII0.26 ± 0.030.15 ± 0.020.09 ± 0.010.09 ± 0.010.25 ± 0.040.20 ± 0.030.15 ± 0.02** 0.23 ± 0.04** 0.24 ± 0.040.15 ± 0.020.14 ± 0.02** 0.20 ± 0.04** 0.22 ± 0.050.14 ± 0.020.10 ± 0.010.14 ± 0.01**

Data represent mean ± SD (n = 6 for each group). 1BW: body weight (g), 2AI = (TC-HDL-C)/HDL-C, 3AAI=HDL-C/TC. TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AI: Atherogenic index; AAI: Anti atherogenic index; NM: High-cholesterol diet group; LD: High-cholesterol diet with Low dosage of K. marxianus M3 group; MD: High-cholesterol diet with middle dosage of K. marxianus M3 group; HD: High-cholesterol diet with high dosage of K. marxianus M3 group.

p <0.05 compared with the control group;

p <0.01 compared with the control group.

Data represent mean ± SD (n = 6 for each group). 1BW: body weight (g), 2AI = (TC-HDL-C)/HDL-C, 3AAI=HDL-C/TC. TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AI: Atherogenic index; AAI: Anti atherogenic index; NM: High-cholesterol diet group; LD: High-cholesterol diet with Low dosage of K. marxianus M3 group; MD: High-cholesterol diet with middle dosage of K. marxianus M3 group; HD: High-cholesterol diet with high dosage of K. marxianus M3 group. p <0.05 compared with the control group; p <0.01 compared with the control group. Moreover, oral administration of various dosages of K. marxianus M3 showed different degrees of changes in serum lipid. The serum TC, TG, and LDL-C levels were the most reduced in the LD group, decreasing by 44.33%, 39.21% and 60.12%, respectively, whereas the serum HDL-C level improved by 44.18% compared to the NM group. In the MD group, the serum TC, TG, and LDL-C levels decreased by 51.01%, 29.41% and 44.3%, respectively, whereas the HDL-C level improved by 16.27%. Moreover, the serum levels of TC, TG and LDL-C in the HD group were decreased by 35.82%, 35.29% and 31.64%, respectively, and the HDL-C level increased by 4.65% (Table 1). As a result, oral administration of K. marxianus M3 in rats significantly decreased (p <0.01) the serum TC, TG, LDL-C levels and atherogenic index (AI), and significantly increased (p <0.01) the serum HDL-C levels and anti-atherogenic index (AAI) compared to the NM group.

Effect on Liver lipid profiles

After 7 weeks of treatment, the liver lipid levels of rats were also examined. As shown in Table 2, oral administration of K. marxianus M3 for 7 weeks significantly decreased (p <0.01) liver TC, TG, LDL-C levels and the AI compared with the NM groups. In addition, the liver HDL-C levels and AII of the K. marxianus M3 treatment group were significantly higher (p <0.01) compared to the NM group. Moreover, oral administration of K. marxianus M3 at various dosages showed different degrees of decreases in liver TC, TG, LDL-C levels and increases in liver HDL-C levels. After 7 weeks of administration, the liver TG, TC, LDL-C levels in the MD group significantly decreased (p <0.01) by 36.00%, 22.92% and 52.94% compared with the NM group. Furthermore, the liver HDL-C contents in the LD group rats reached 0.31 ± 0.10 mmol/L, which was 72.22% higher than that in the NM group. As a result, K. marxianus M3 treatment in the LD group significantly decreased (p <0.01) the liver AI and increased (p <0.01) the liver AII compared with the NM group.
Table 2

Effect of Kluyveromyces marxianus from Tibetan Kefir on hepatic lipid profiles of rats ( ± s, n = 10).

TC (mmol/L)TG (mmol/L)HDL-C (mmol/L)LDL-C (mmol/L)AIAAI
NM0.25 ± 0.070.48 ± 0.090.18 ± 0.070.17 ± 0.130.37 ± 0.070.73 ± 0.11
LD0.16 ± 0.05** 0.37 ± 0.07** 0.31 ± 0.10** 0.08 ± 0.05** −0.50 ± 0.07** 2.11 ± 0.11**
MD0.19 ± 0.04** 0.42 ± 0.11DD 0.27 ± 0.11** 0.13 ± 0.04DD −0.32 ± 0.04** 1.51 ± 0.09**
HD0.20 ± 0.05** 0.41 ± 0.08DD 0.25 ± 0.13** 0.14 ± 0.05DD −0.23 ± 0.06** 1.33 ± 0.10**

Data represent mean ± SD (n = 10 for each group). AI = (TC-HDL-C)/HDL-C, AAI=HDL-C/TC. TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AI: Atherogenic index; AAI: Anti atherogenic index; NM: High-cholesterol diet group; LD: High-cholesterol diet with Low dosage of K. marxianus M3 group; MD: High-cholesterol diet with middle dosage of K. marxianus M3 group; HD: High-cholesterol diet with high dosage of K. marxianus M3 group.

p <0.05 compared with the control group;

p <0.01 compared with the control group.

Data represent mean ± SD (n = 10 for each group). AI = (TC-HDL-C)/HDL-C, AAI=HDL-C/TC. TC: Total cholesterol; TG: Triglyceride; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; AI: Atherogenic index; AAI: Anti atherogenic index; NM: High-cholesterol diet group; LD: High-cholesterol diet with Low dosage of K. marxianus M3 group; MD: High-cholesterol diet with middle dosage of K. marxianus M3 group; HD: High-cholesterol diet with high dosage of K. marxianus M3 group. p <0.05 compared with the control group; p <0.01 compared with the control group.

Effects on viscera organs

As shown in Table 3, a high cholesterol diet increased the heart, liver and kidney weight of the rats. After 7 weeks of administration, the viscera weight (heart, liver and kidney weight) and viscera coefficients in the rats of the LD group were significantly lower (p <0.01) compare to the NM group. The heart weight, heart coefficient, liver weight and liver coefficient in the MD and HD groups were also significantly decreased (p <0.01) compared to the NM group. Moreover, the kidney weight and kidney coefficient in the MD and HD groups were significantly decreased (p <0.05) compared to the NM group.
Table 3

Effect of Kluyveromyces marxianus from Tibetan Kefir on visceral weight and visceral coefficient of rats ( ± s, n = 10).

Heart weight (g)Cardiac coefficient (%)Liver weight (g)Liver coefficient (%)Renal weight (g)Renal coefficient (%)
NM1.28 ± 0.170.48 ± 0.0412.56 ± 1.724.81 ± 0.211.73 ± 0.170.64 ± 0.06
LD0.81 ± 0.11** 0.28 ± 0.02** 8.86 ± 1.14** 3.24 ± 0.14** 1.47 ± 0.11** 0.54 ± 0.04**
MD0.85 ± 0.15** 0.30 ± 0.03** 9.23 ± 1.37** 3.43 ± 0.17** 1.54 ± 0.14DD 0.57 ± 0.02DD
HD0.87 ± 0.13** 0.33 ± 0.04** 9.31 ± 1.21** 3.45 ± 0.16** 1.60 ± 0.18DD 0.60 ± 0.03DD

Data represent mean ± SD (n = 10 for each group). Cardiac coefficient = heart weight/body weight; Liver coefficient = liver weight/body weight; Renal coefficient = renal weight/body weight; NM: High-cholesterol diet group; LD: High-cholesterol diet with Low dosage of K. marxianus M3 group; MD: High-cholesterol diet with middle dosage of K. marxianus M3 group; HD: High-cholesterol diet with high dosage of K. marxianus M3 group.

p <0.05 compared with the control group;

p <0.01 compared with the control group.

Data represent mean ± SD (n = 10 for each group). Cardiac coefficient = heart weight/body weight; Liver coefficient = liver weight/body weight; Renal coefficient = renal weight/body weight; NM: High-cholesterol diet group; LD: High-cholesterol diet with Low dosage of K. marxianus M3 group; MD: High-cholesterol diet with middle dosage of K. marxianus M3 group; HD: High-cholesterol diet with high dosage of K. marxianus M3 group. p <0.05 compared with the control group; p <0.01 compared with the control group. We further examined the hepatic morphology in rats. As shown in Figure 1a, in the NM group rats, the structure of the hepatic lobule had disappeared, and the liver cell morphology was irregular. There were different degrees of edema, focal necrosis, and fatty degeneration of liver cells. Moreover, the liver cells exhibited massive fatty changes and severe steatosis with cytoplasmic vacuoles, and the infiltration of inflammatory cells were visible. Taken together, these conditions suggested damage due to a high-cholesterol diet on the hepatic cells. In contrast, the size of the lipid droplets in the LD group was remarkably smaller than those in the NM group (Figure 1b), and the hepatic cells exhibited normal histology. In addition, the lipid droplets in the MD and HD groups were also reduced in varying degrees (Figure 1c, d). Taken together, our results indicated that K. marxianus M3 treatment reduced the build-up of lipid droplets and maintained normal hepatocytes.
Figure 1

Histology of liver steatosis in rats. A: high-cholesterol diet group; B: high-cholesterol diet+K. marxianus M3 (5 mL/kg); C: high-cholesterol diet+K. marxianus M3 (10 mL/kg); D: high-cholesterol diet+K. marxianus M3 (20 mL/kg). All the photomicrographs show HE staining (original magnification × 100).

Discussion

Recently, considerable attention has focused on the potential of probiotics in altering lipid metabolism. This interest stems from growing evidence that probiotics reduce the concentration of cholesterol in vivo (Mohan ; Abdulrahim ; Panda ; Nguyen ; Wang ; Alkhalf ; Wang ). Generally, a high-cholesterol diet can increase body weight (Xie ). According to our results, addition of K. marxianus M3 live yeast with high-cholesterol diet did not significantly change the body weight of rats. However, K. marxianus M3 treatment for 7 weeks significantly decreased (p <0.01) the serum TC, TG and LDL-C levels in rats. In particular, these effects were more evident in the LD group (TC, TG and LDL-C reduced by 51.01%, 39.22% and 60.13%, respectively) (Table 1). Our results indicated that there was a relationship between the formation and reduction of the metabolism of cholesterol in the serum. Similar results were reported for the cholesterol-reducing activity of yeast (Yalçin ; Yalçin ), Lactobacillus (Nielson and Gilliland, 1985, Gilliland ; Hashimoto ; Simons ; Nguyen ; Xie ; Wang ) and Bacillus (Fukushima and Nakao, 1995). High concentrations of TC and LDL-C are strongly associated with an increased risk of coronary heart disease. A reduction in TC and LDL-C in a hypercholesterolemic individual can reduce the incidence of cardiovascular disease (Probstfield and Rifkind 1991). Moreover, elevated levels of oxidized LDL-C are associated with artherosclerotic plaque formation on the artery walls, but increased HDL-C levels may reduce the risk due to the ability of HDL to transport cholesterol back to the liver for excretion or to other tissues of cardiovascular disease (Lewis ). According to our results, K. marxianus M3 supplementation dramatically increased the serum HDL-C level (p <0.01, p <0.05) in rats (Table 1). As a result, the AI of the K. marxianus M3 treatment groups was significantly decreased (p <0.01) compared to the NM group. Thus, we confirmed that K. marxianus M3 exerted a hypolipidemic effect and could alleviate lipid related metabolic syndrome. Similar results were reported by Hashimoto , in which a diet containing L. casei TMC 0409 increased the concentration of HDL-C in blood, which was consistent with other studies (Akalin ; Danielson ; De Smet ). However, conflicting results were reported (Chiu ; St-Onge ; Keim et al., 1981, Rossouw et al., 1981; De Roos ) in humans and animals. In general, cholesterol is indispensable to the human body, and its levels are subjected to complex regulation. Cholesterol is modified into oxysterols, including 22- and 24-hydroxy cholesterol, when excess cholesterol is deposited in hepatic cells (Satoshi Hirako ). As expected, we demonstrated that the high-cholesterol diet increased hepatic TC, TG and LDL-C levels in rats (Table 2). Rats supplemented with K. marxianus M3 displayed significant reductions in hepatic TC, TG and LDL-C levels. These findings demonstrated that the serum cholesterol and TG levels in K. marxianus M3-treated rats were reduced, rather than merely being redistributed from the blood to the liver. Moreover, our results were consistent with previous reports (Kumar ; Chiu ). In this study, a high-cholesterol diet promoted the visceral weight (heart, liver and renal) in rats (Table 3). In addition, oral administration of K. marxianus M3 significantly reduced the visceral weights and visceral coefficients, suggesting a protection of K. marxianus M3 to the visceral organs under a high-cholesterol diet. Moreover, the histology of liver steatosis also supported this result. High-cholesterol diet caused different degrees of edema, focal necrosis, and fatty degeneration of liver cells (Figure 1a). In contrast, the K. marxianus M3 treatment could reduce the build-up of lipid droplets and maintained normal hepatocytes (Figure 1b, c). The result of liver tectology proved that the K. marxianus M3 had important potential in alleviating hepatic steatosis attributed to mediation of lipid metabolism and had protective effects on hepatic structure. Similar results have also been reported (Wang ; Xie ). In recent yeas, several hypotheses have been proposed to explain the hypocholesterolemic effects of the probiotic strains: (1) consumption or absorption of cholesterol by probiotic strains (Pigeon ; Liong and Shah 2005); (2) the cholesterol is converted into coprostanol by cholesterol reductase, which is produced by probiotic strains (Lye et al., 2010); (3) some probiotic strains excrete bile salt hydrolase, leading to increased bile excretion in feces (Begley et al., 2010), etc. There are some reports on bile salt hydrolase in different species of Lactobacillus, Enterococcus, Peptostreptococcus, Bifidobacterium, Clostridium, and Bacteroides (Liong and Shah 2005; Begley et al., 2010). In our previous research, we have cloned the bile salt hydrolase (bsh) gene in K. marxianus (Genebank Acession: JQ247427.1). So we proposed that the hypocholesterolemic effects of K. marxianus M3 might cased by the activity of bile salt hydrolase. And further research could be conduct in this field. In conclusion, our results suggested that K. marxianus M3 is a safe probiotic with the potential to reduce serum cholesterol and triglyceride levels. Thus, further studies are required to determine the mechanism underlying the cholesterol-lowering effect. It will also be necessary to test more animals, utilizing varying doses of K. marxianus M3 over longer time periods, to assess the long-term probiotic potential of K. marxianus M3.
  39 in total

1.  Functional characteristics of Lactobacillus spp. from traditional Maasai fermented milk products in Kenya.

Authors:  Julius Maina Mathara; Ulrich Schillinger; Claudia Guigas; Charles Franz; Phillip Museve Kutima; Samuel K Mbugua; H-K Shin; Wilhelm H Holzapfel
Journal:  Int J Food Microbiol       Date:  2008-05-06       Impact factor: 5.277

2.  Influence of yogurt and acidophilus yogurt on serum cholesterol levels in mice.

Authors:  A S Akalin; S Gönç; S Düzel
Journal:  J Dairy Sci       Date:  1997-11       Impact factor: 4.034

3.  The effects of Lactobacillus-fermented milk on lipid metabolism in hamsters fed on high-cholesterol diet.

Authors:  Chiu-Hsia Chiu; Tzu-Yu Lu; Yun-Yu Tseng; Tzu-Ming Pan
Journal:  Appl Microbiol Biotechnol       Date:  2005-09-20       Impact factor: 4.813

4.  Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity.

Authors:  I De Smet; P De Boever; W Verstraete
Journal:  Br J Nutr       Date:  1998-02       Impact factor: 3.718

5.  Lactic acid bacteria and yeasts in kefir grains and kefir made from them.

Authors:  E Simova; D Beshkova; A Angelov; Ts Hristozova; G Frengova; Z Spasov
Journal:  J Ind Microbiol Biotechnol       Date:  2002-01       Impact factor: 3.346

6.  Protective effects of two Lactobacillus plantarum strains in hyperlipidemic mice.

Authors:  Li-Xin Wang; Kai Liu; Da-Wei Gao; Ji-Kui Hao
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

7.  Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study.

Authors:  M R Law; N J Wald; T Wu; A Hackshaw; A Bailey
Journal:  BMJ       Date:  1994-02-05

8.  Anticholesteremic property of Lactobacillus acidophilus yogurt fed to mature boars.

Authors:  A D Danielson; E R Peo; K M Shahani; A J Lewis; P J Whalen; M A Amer
Journal:  J Anim Sci       Date:  1989-04       Impact factor: 3.159

Review 9.  Water-soluble dietary fibers and cardiovascular disease.

Authors:  Elke Theuwissen; Ronald P Mensink
Journal:  Physiol Behav       Date:  2008-01-05

10.  The obesity and fatty liver are reduced by plant-derived Pediococcus pentosaceus LP28 in high fat diet-induced obese mice.

Authors:  Xingrong Zhao; Fumiko Higashikawa; Masafumi Noda; Yusuke Kawamura; Yasuyuki Matoba; Takanori Kumagai; Masanori Sugiyama
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  7 in total

Review 1.  Modelling hypercholesterolaemia in rats using high cholesterol diet.

Authors:  Luiza Ferracini Cunha; Mariana Aubin Ongaratto; Marcelo Endres; Alethea Gatto Barschak
Journal:  Int J Exp Pathol       Date:  2021-03-12       Impact factor: 1.925

2.  The Cholesterol-Lowering Effect of Alisol Acetates Based on HMG-CoA Reductase and Its Molecular Mechanism.

Authors:  Fei Xu; Hui Yu; Cai Lu; Jun Chen; Wei Gu
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-30       Impact factor: 2.629

Review 3.  Anti-Obesity Effects of Medicinal and Edible Mushrooms.

Authors:  Kumar Ganesan; Baojun Xu
Journal:  Molecules       Date:  2018-11-05       Impact factor: 4.411

4.  Probiotic Properties of Enterococcus Isolated From Artisanal Dairy Products.

Authors:  Yousef Nami; Reza Vaseghi Bakhshayesh; Hossein Mohammadzadeh Jalaly; Hajie Lotfi; Solat Eslami; Mohammad Amin Hejazi
Journal:  Front Microbiol       Date:  2019-02-26       Impact factor: 5.640

Review 5.  Edible Mushrooms as Novel Myco-Therapeutics: Effects on Lipid Level, Obesity and BMI.

Authors:  Faheem Mustafa; Hitesh Chopra; Atif Amin Baig; Satya Kumar Avula; Sony Kumari; Tapan Kumar Mohanta; Muthupandian Saravanan; Awdhesh Kumar Mishra; Nanaocha Sharma; Yugal Kishore Mohanta
Journal:  J Fungi (Basel)       Date:  2022-02-21

Review 6.  Bioprospecting Kluyveromyces marxianus as a Robust Host for Industrial Biotechnology.

Authors:  Muhammad Bilal; Liyun Ji; Yirong Xu; Shuo Xu; Yuping Lin; Hafiz M N Iqbal; Hairong Cheng
Journal:  Front Bioeng Biotechnol       Date:  2022-04-20

Review 7.  Bioactivities and Health Benefits of Mushrooms Mainly from China.

Authors:  Jiao-Jiao Zhang; Ya Li; Tong Zhou; Dong-Ping Xu; Pei Zhang; Sha Li; Hua-Bin Li
Journal:  Molecules       Date:  2016-07-20       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.